Prepared by Dr. Yuki Tanaka, CFA, Director of US Markets | Reviewed by James Wilson, Lead Editor | Report ID: IGEMINI-EBB6004F-20260531 | Data as of 2026-05-31
Executive Summary: Our multi-factor model assigns magi medicare a Bullish outlook for the next quarter. Key drivers include a P/E of 31.7x, 16.3% revenue expansion, and an RSI of 62 suggesting a neutral-bullish phase. We define critical support at $1072.8 and resistance at $1311.2.
Rating: Buy | Target Price: $1585.36 | Next Earnings: Jun 22
Download Full PDF Report
Price action carved a Double Bottom, confirmed by a 1.25x volume spike on May 26, 2026. The resistance at $1311.2 was tested.
On-chain money flow shows 32%% increase in smart money index, reinforcing the technical setup.
Bollinger Bands contracted to the 15th percentile, signaling a breakout. A close above $1370.8 would be bullish.
EPS of $37.6 reveals high earnings quality. DuPont analysis highlights operating leverage as the key ROE driver.
Relative to Technology peers, magi medicare sits at the 76th percentile in valuation, offering a potential value opportunity.
Short float at 3.7% is below the sector average, reducing squeeze risk. Institutional ownership is 74%.
Dark pool prints show a 25%% surge in block trades, indicating institutional accumulation before Jun 22 earnings.
Beta of 0.95 suggests magi medicare is {beta_desc} volatile than the market, influencing hedging strategies.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $1192 | $1132.4 |
| Market Cap | $13.91B | $16.69B |
| P/E Ratio | 31.7x | 26.9x |
| EPS (TTM) | $37.6 | $33.84 |
| Dividend Yield | 0.82% | 0.6% |
| Revenue Growth | 16.3% | 9.8% |
| Target Price | $1585.36 | - |
| Beta | 0.95 | 1.00 |